ArticleSystematic reviews2026
Disease burden estimates in economic evaluation studies of Respiratory Syncytial Virus (RSV) maternal immunization: a systematic review protocol.
Article in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) is a highly contagious pathogen and a leading cause of bronchiolitis and pneumonia in young children, posing a significant global health burden. Currently, there are no effective treatment options available. Maternal immunization has emerged as a promising strategy to protect newborns from RSV. The RSVPref vaccine has shown efficacy in reducing RSV hospitalizations and severe cases in newborns aged 3 to 6 months. Economic evaluations of maternal RSV vaccination are increasingly used to inform healthcare decision-making and resource allocation. These evaluations rely heavily on accurate disease burden estimates based on robust epidemiological data, as these assumptions strongly influence cost-effectiveness results and vaccine introduction decisions. This systematic review provides an overview of economic evaluations of RSV maternal immunization, with a focus on methods for estimating the epidemiological disease burden.
methodsWe will systematically search for studies in MEDLINE (via PubMed), EMBASE, the NHS Economic Evaluation Database (NHS EED), the HTA database, the Tufts CEA Registry, LILACS, and Web of Science. The search strategy will encompass three main categories, (1) economic evaluation, (2) vaccines, and (3) respiratory syncytial viruses, including studies published since 2000 in any language. Two independent reviewers will extract data via a validated form. The quality of reporting of the included studies will be assessed via the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. A descriptive and interpretative synthesis of the obtained extracted data will be performed. DISCUSSION: RSV immunization is the most crucial option for reducing the disease burden imposed by the virus in children. This study will systematically review the methodologies used to develop accurate and reliable epidemiological estimates, which are essential components of economic evaluation studies that will support the global implementation of the RSV maternal vaccine. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024549989.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.